 |
The
incidence of type 2 diabetes in the United Kingdom from
1991 to 2010 |
| |
There was a significant increase
in the incidence of diagnosed type 2 diabetes between 1991
and 2010 and the proportion of people diagnosed at an earlier
age has increased markedl (Diabetes, Obesity and Metabolism) |
| |
|
|
Estimating
the Population Prevalence of Diagnosed and Undiagnosed
Diabetes |
| |
A substantial proportion of
diabetes cases are missed by surveillance methods that
use health administrative databases. This finding is concerning
because individuals with undiagnosed diabetes are likely
to have a delay in treatment and, thus, a higher risk for
diabetes-related complications (Diabetes Care) |
| |
|
|
Epidemiology
of blindness attributable to diabetes in Scotland: change
over 20 years in a defined population |
| |
Over the decade 2000–2009,
the incidence of blindness attributable to diabetes fell
by a mean of 10.6% per year in the population with diabetes
(Diabetic Medicine) |
| |
|
|
Audit
of clinical practice in the use of incretin mimetic agents
for the management of patients with type 2 diabetes |
| |
It was concluded that good metabolic
control can be achieved if these agents are used judiciously.
The DPP-4 inhibitors improve HbA1c but are weight neutral,
while the GLP-1R agonists cause both weight loss and improvements
in HbA1c. The addition of insulin under specialist supervision
can be beneficial (Practical Diabetes) |
| |
|
|
Combination
therapy of dipeptidyl peptidase-4 inhibitors and metformin
in type 2 diabetes: Rationale and evidence |
| |
This article provides an overview
of clinical evidence and discusses the rationale for the
combination therapy of DPP-4 inhibitors and metformin (Diabetes,
Obesity and Metabolism) |
| |
|
|
Relationship
between serum levels of triglycerides and vascular inflammation,
measured as COX-2, in arteries from diabetic patients:
a translational study |
| |
We conclude that is not the
glucose blood levels but the triglicerydes leves what increases
the expression of COX-2 in arteries from DP (Lipids in
Health and Disease) |
| |
|
|
Clinical,
metabolic and psychological outcomes and treatment costs
of a prospective randomized trial based on different
educational strategies to improve diabetes care (PRODIACOR) |
| |
In a primary care setting, educational
interventions combined with comprehensive care coverage
resulted in long-term improvement in clinical, metabolic
and psychological outcomes at the best cost-effectiveness
ratio (Diabetic Medicine) |
| |
|
|
Urinary
C-peptide creatinine ratio detects absolute insulin deficiency
in Type 2 diabetes |
| |
The urinary C-peptide creatinine
ratio is a practical non-invasive method to aid detection
of absolute insulin deficiency, with a urinary C-peptide
creatinine ratio > 0.2nmol/mmol being a reliable indicator of retained endogenous insulin secretion
(Diabetic Medicine) |
| |
|
|
Mortality
outcomes of different sulfonylurea drugs. The results
of a 14-year cohort study of type 2 diabetic patients |
| |
Cancer mortality was markedly
reduced in the patients on gliclazide and tolbutamide.
These results suggest additional benefits for these drugs
beyond their blood glucose-lowering effect and strongly
advocate for further investigation (European Journal of
Endocrinology) |
| |
|
|
Sulphonylureas
and risk of cardiovascular disease: systematic review
and meta-analysis |
| |
Results suggest that sulphonylurea
use may elevate the risk of cardiovascular disease among
patients with diabetes (Diabetic Medicine) |
| |
|
|
Dapagliflozin
a Glucose-Regulating Drug With Diuretic Properties in
Subjects With Type 2 Diabetes |
| |
Dapagliflozin-induced SGLT2
inhibition for 12 weeks is associated with reductions in
24-hour BP, body weight, GFR, and possibly plasma volume.
Cumulatively, these effects suggest that dapagliflozin
may have a diuretic-like capacity to lower BP in addition
to beneficial effects on glycemic control (Diabetes, Obesity
and Metabolism) |
| |
|
